Stocktoria
Chugai Pharmaceutical Co., Ltd. 4519.T
JP · Tokyo Stock Exchange · XTKS · stock · Healthcare · website
Chugai Pharmaceutical Co., Ltd. financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | ¥1.26T | ¥1.17T | ¥1.11T | ¥1.26T |
| Gross profit | ¥894.3B | ¥831.2B | ¥698.1B | ¥783.5B |
| R&D expense | ¥187.6B | ¥181.4B | ¥174.9B | ¥149.6B |
| SG&A expense | ¥116.5B | ¥110.1B | ¥112.6B | ¥100.5B |
| Operating income | ¥598.8B | ¥542.0B | ¥439.2B | ¥533.3B |
| Interest expense | ¥207.0M | — | ¥27.0M | ¥61.0M |
| Income tax | ¥163.8B | ¥155.7B | ¥118.3B | ¥156.7B |
| Operating cash flow | ¥386.3B | ¥447.6B | ¥409.9B | ¥243.6B |
| Free cash flow | ¥274.7B | ¥392.7B | ¥335.7B | ¥172.3B |
| Cash & equivalents | ¥426.6B | ¥540.2B | ¥458.7B | ¥222.2B |
| Inventory | ¥276.8B | ¥240.1B | ¥273.5B | ¥292.2B |
| Total assets | ¥2.47T | ¥2.21T | ¥1.93T | ¥1.87T |
| Total liabilities | ¥442.9B | ¥306.9B | ¥307.0B | ¥445.4B |
| Shareholders' equity | ¥2.03T | ¥1.90T | ¥1.63T | ¥1.42T |
| Share buybacks | ¥6.0M | ¥10.0M | ¥5.0M | ¥5.0M |
| EPS (diluted) | ¥263.72 | ¥235.36 | ¥197.80 | ¥227.57 |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +7.5% | +5.3% | -11.8% | — |
| EPS growth | +12.0% | +19.0% | -13.1% | — |
| Free cash flow growth | -30.1% | +17.0% | +94.8% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · JP · as of 2025-12-31. Figures in JPY. Facts plus Stocktoria's own computed scores — not investment advice.